Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Previously Marketed

4

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

DNA topoisomerase II

4

Topoisomerase IV

4

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1997

4

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Acute bacterial exacerbations of chronic bronchitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis

4

Community-acquired pneumonia caused by Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, or Mycoplasma pneumonia

4

Uncomplicated gonorrhea (urethral In males and endocervical and rectal in females) caused by Neissen'a gononrhoeae

4

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

4

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Otsuka Pharmaceutical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

4

PUBCHEM

4

MERCK INDEX

3

CAS

2

ChEMBL

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIBACTERIALS FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

QUINOLONE ANTIBACTERIALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Fluoroquinolones

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

3

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

GREPAFLOXACIN HYDROCHLORIDE

A4ER1Z8N9N

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1997

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Topoisomerase IV

DNA topoisomerase II

Conditions:

Community-acquired pneumonia caused by Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, or Mycoplasma pneumonia

Acute bacterial exacerbations of chronic bronchitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis

Uncomplicated gonorrhea (urethral In males and endocervical and rectal in females) caused by Neissen'a gononrhoeae

Grepafloxacin is a monofluorinated quinolone with a cyclopropyl group at position 1, a 3-methyl-1piperazinyl group at position 7 and a methyl substitution at the 5 position, that was synthesized by Otsuka in Japan. It exhibited in vitro activity agai...

nst a wide variety of both Gram-positive and Gram-negative bacteria including anaerobic species. The compound was reported to have a broad spectrum of activity, particularly against pathogens responsible for community-acquired respiratory infections including those caused by beta-lactam and macrolide-resistant strains of Streptococcus pneumoniae and Haemophilus influenzae. Japanese researchers also reported that unlike other quinolones, grepafloxacin reached high levels in the bile and might also be useful in the treatment of biliary tract infection. Grepafloxacin was administered once daily and did not require dosage adjustment for renal insufficiency, but grepafloxacin tablets were contraindicated in patients with hepatic failure. Otsuka Pharmaceutical signed a licensing agreement for grepafloxacin with GlaxoSmithKline. According to this agreement, GlaxoSmithKline had marketing rights to grepafloxacin in Europe, USA, and certain other markets. Otsuka retained rights for Japan and some Asian countries

GREPAFLOXACIN DIHYDRATE

NO045R4X1D

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1997

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Topoisomerase IV

DNA topoisomerase II

Conditions:

Community-acquired pneumonia caused by Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, or Mycoplasma pneumonia

Acute bacterial exacerbations of chronic bronchitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis

Uncomplicated gonorrhea (urethral In males and endocervical and rectal in females) caused by Neissen'a gononrhoeae

Grepafloxacin is a monofluorinated quinolone with a cyclopropyl group at position 1, a 3-methyl-1piperazinyl group at position 7 and a methyl substitution at the 5 position, that was synthesized by Otsuka in Japan. It exhibited in vitro activity agai...

nst a wide variety of both Gram-positive and Gram-negative bacteria including anaerobic species. The compound was reported to have a broad spectrum of activity, particularly against pathogens responsible for community-acquired respiratory infections including those caused by beta-lactam and macrolide-resistant strains of Streptococcus pneumoniae and Haemophilus influenzae. Japanese researchers also reported that unlike other quinolones, grepafloxacin reached high levels in the bile and might also be useful in the treatment of biliary tract infection. Grepafloxacin was administered once daily and did not require dosage adjustment for renal insufficiency, but grepafloxacin tablets were contraindicated in patients with hepatic failure. Otsuka Pharmaceutical signed a licensing agreement for grepafloxacin with GlaxoSmithKline. According to this agreement, GlaxoSmithKline had marketing rights to grepafloxacin in Europe, USA, and certain other markets. Otsuka retained rights for Japan and some Asian countries

GREPAFLOXACIN HYDROCHLORIDE HYDRATE

5487J3Q1MN

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1997

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Topoisomerase IV

DNA topoisomerase II

Conditions:

Community-acquired pneumonia caused by Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, or Mycoplasma pneumonia

Acute bacterial exacerbations of chronic bronchitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis

Uncomplicated gonorrhea (urethral In males and endocervical and rectal in females) caused by Neissen'a gononrhoeae

Grepafloxacin is a monofluorinated quinolone with a cyclopropyl group at position 1, a 3-methyl-1piperazinyl group at position 7 and a methyl substitution at the 5 position, that was synthesized by Otsuka in Japan. It exhibited in vitro activity agai...

nst a wide variety of both Gram-positive and Gram-negative bacteria including anaerobic species. The compound was reported to have a broad spectrum of activity, particularly against pathogens responsible for community-acquired respiratory infections including those caused by beta-lactam and macrolide-resistant strains of Streptococcus pneumoniae and Haemophilus influenzae. Japanese researchers also reported that unlike other quinolones, grepafloxacin reached high levels in the bile and might also be useful in the treatment of biliary tract infection. Grepafloxacin was administered once daily and did not require dosage adjustment for renal insufficiency, but grepafloxacin tablets were contraindicated in patients with hepatic failure. Otsuka Pharmaceutical signed a licensing agreement for grepafloxacin with GlaxoSmithKline. According to this agreement, GlaxoSmithKline had marketing rights to grepafloxacin in Europe, USA, and certain other markets. Otsuka retained rights for Japan and some Asian countries

GREPAFLOXACIN

L1M1U2HC31

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1997

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Topoisomerase IV

DNA topoisomerase II

Conditions:

Community-acquired pneumonia caused by Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, or Mycoplasma pneumonia

Acute bacterial exacerbations of chronic bronchitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis

Uncomplicated gonorrhea (urethral In males and endocervical and rectal in females) caused by Neissen'a gononrhoeae

Grepafloxacin is a monofluorinated quinolone with a cyclopropyl group at position 1, a 3-methyl-1piperazinyl group at position 7 and a methyl substitution at the 5 position, that was synthesized by Otsuka in Japan. It exhibited in vitro activity agai...

nst a wide variety of both Gram-positive and Gram-negative bacteria including anaerobic species. The compound was reported to have a broad spectrum of activity, particularly against pathogens responsible for community-acquired respiratory infections including those caused by beta-lactam and macrolide-resistant strains of Streptococcus pneumoniae and Haemophilus influenzae. Japanese researchers also reported that unlike other quinolones, grepafloxacin reached high levels in the bile and might also be useful in the treatment of biliary tract infection. Grepafloxacin was administered once daily and did not require dosage adjustment for renal insufficiency, but grepafloxacin tablets were contraindicated in patients with hepatic failure. Otsuka Pharmaceutical signed a licensing agreement for grepafloxacin with GlaxoSmithKline. According to this agreement, GlaxoSmithKline had marketing rights to grepafloxacin in Europe, USA, and certain other markets. Otsuka retained rights for Japan and some Asian countries

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1